Hyperphosphatemia Drugs Market to Witness Increasing Revenue Growth During the Forecast Period 2021–2028
Hyperphosphatemia is exceptionally normal in individuals with ongoing kidney sickness all the more frequently in individuals with end-stage kidney illness. Some other potential reasons for hyperphosphatemia incorporates diabetic ketoacidosis, uncontrolled diabetes, high nutrient D levels, and low parathyroid chemical levels.
Hyperphosphatemia Drugs Market Drivers
Expanding dispatches and endorsement of novel drugs in key districts are relied upon to fuel the worldwide hyperphosphatemia drugs market development in not so distant future. For example, in 2016, Astellas Pharma Inc. gotten marketing endorsement for its Kiklin Granules 86.2%, showed for the therapy of hyperphosphatemia in patients with constant kidney sickness in Japan. In 2015, Keryx Biopharmaceuticals, Inc. gotten endorsement from European Commission for new medication Fexeric (R) (ferric citrate coordination complex), showed for the therapy of hyperphosphatemia in grown-ups with ongoing kidney infection.
The hyperphosphatemia drugs market in Asia Pacific is expected to grow at a fast speed during the conjecture time frame. The hyperphosphatemia drugs market in India and China is expected to grow at the most noteworthy CAGR during the estimate time frame. Expansion in geriatric populace in China and India is projected to drive the hyperphosphatemia drugs market in Asia Pacific. There is an assessment that India's geriatric populace will expand essentially consistently.
Key players operating in the global hyperphosphatemia drugs market include Amag Pharmaceuticals, Johnson And Johnson, Cipla, DSM Sinochem Pharmaceuticals, Keryx Biopharmaceuticals, Pharmacal, Sun Pharm Inc., Zeria Pharmaceutical, Ultragenyx, Bruno Pharmaceutical Spa, Fermenta Biotech Ltd, Pfizer Inc., Roche Diagnostics Corporation, R.H. Moore Drug Co., Vifor Pharma, Sanofi, Shire, and Fresenius Medical Care.
Comments
Post a Comment